Key result
Aliskiren treatment for 28 days reduced blood pressure to wild-type levels and ameliorated renal interstitial fibrosis and inflammation in 10-month-old renin transgenic mice.
Why the study?
Does aliskiren reverse renal disease and cardiac hypertrophy in a transgenic mouse model of hypertensive chronic kidney disease?
Population
10-month-old renin transgenic mice and age-matched wild-type mice
Comparison
Aliskiren administered for 28 days vs Placebo, untreated wild-type mice, and hydralazine
Design
Preclinical
Follow-up
28 days
Authors
Loading...
Preclinical data in renin transgenic mice are hypothesis-generating; leaves open whether aliskiren reverses renal fibrosis in human hypertensive CKD.
Does aliskiren reverse renal disease and cardiac hypertrophy in a transgenic mouse model of hypertensive chronic kidney disease?
Direct renin inhibition with aliskiren reverses renal fibrosis and cardiac hypertrophy in a hypertensive mouse model, demonstrating nephroprotective effects independent of blood pressure lowering.
Kavvadas et al. (2013) studied Hypertensive chronic kidney disease. Aliskiren vs. Placebo was evaluated on Blood pressure, proteinuria, cardiac hypertrophy, and renal fibrosis. Aliskiren treatment for 28 days reduced blood pressure to wild-type levels and ameliorated renal interstitial fibrosis and inflammation in 10-month-old renin transgenic mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: